SAN

76.23

+0.77%↑

ARGX

762.4

+1.03%↑

SHL.DE

34.72

+0.35%↑

PHIA

22.52

-0.18%↓

FRE

37.44

-0.61%↓

SAN

76.23

+0.77%↑

ARGX

762.4

+1.03%↑

SHL.DE

34.72

+0.35%↑

PHIA

22.52

-0.18%↓

FRE

37.44

-0.61%↓

SAN

76.23

+0.77%↑

ARGX

762.4

+1.03%↑

SHL.DE

34.72

+0.35%↑

PHIA

22.52

-0.18%↓

FRE

37.44

-0.61%↓

SAN

76.23

+0.77%↑

ARGX

762.4

+1.03%↑

SHL.DE

34.72

+0.35%↑

PHIA

22.52

-0.18%↓

FRE

37.44

-0.61%↓

SAN

76.23

+0.77%↑

ARGX

762.4

+1.03%↑

SHL.DE

34.72

+0.35%↑

PHIA

22.52

-0.18%↓

FRE

37.44

-0.61%↓

Home・Lista de Ações・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Abrir

SetorSaúde

58.3 0.43

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

57.7

Máximo

58.55

Indicadores-chave
By Trading Economics
Rendimento	-33M 9.5M
Vendas	-66M 152M
P/E Médio do Setor	24.641 49.052
EPS	0.185
Margem de lucro	6.216
Funcionários	1,950
EBITDA	-45M 18M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+27.78% upside

Dividendos
By Acuity
Próximos Ganhos	23 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-1.1B 3B
Abertura anterior	57.87
Fecho anterior	58.3

Sentimento de Notícias

By Acuity

50%

154 / 344 Ranking em Healthcare

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de jun. de 2026, 23:36 UTC

Correction to Oracle Reports Higher 4Q Profit Article

10 de jun. de 2026, 23:19 UTC

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 de jun. de 2026, 23:09 UTC

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 de jun. de 2026, 23:04 UTC

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 de jun. de 2026, 20:44 UTC

Caterpillar Raises Quarterly Dividend 8%

10 de jun. de 2026, 23:49 UTC

Elliott: Northern Star Should Take No Options Off The Table

10 de jun. de 2026, 23:48 UTC

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 de jun. de 2026, 23:48 UTC

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 de jun. de 2026, 23:47 UTC

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 de jun. de 2026, 23:47 UTC

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 de jun. de 2026, 23:46 UTC

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 de jun. de 2026, 23:38 UTC

Global Equities Roundup: Market Talk

10 de jun. de 2026, 23:38 UTC

Global Forex and Fixed Income Roundup: Market Talk

10 de jun. de 2026, 23:38 UTC

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 de jun. de 2026, 23:32 UTC

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 de jun. de 2026, 23:20 UTC

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 de jun. de 2026, 22:05 UTC

Correction to Bank of Canada Stays on Hold Market Talk

10 de jun. de 2026, 21:57 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 21:52 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 21:35 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 21:22 UTC

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 de jun. de 2026, 20:50 UTC

Tech, Media & Telecom Roundup: Market Talk

10 de jun. de 2026, 20:50 UTC

Financial Services Roundup: Market Talk

10 de jun. de 2026, 20:50 UTC

Basic Materials Roundup: Market Talk

10 de jun. de 2026, 20:50 UTC

Health Care Roundup: Market Talk

10 de jun. de 2026, 20:39 UTC

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 de jun. de 2026, 20:34 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 20:33 UTC

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 de jun. de 2026, 20:33 UTC

Global Equities Roundup: Market Talk

10 de jun. de 2026, 20:33 UTC

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Comparação entre Pares

Variação de preço

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

27.78% parte superior

Previsão para 12 meses

Média 73.6 EUR 27.78%

Máximo 83 EUR

Mínimo 64.2 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

Comprar

Manter

Vender

Com base em 2 analistas que deram avaliações de ações para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Sentimento

By Acuity

154 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.